跳至主要内容
临床试验/NCT01408823
NCT01408823已完成不适用

Pharmacokinetics of Epsilon-Aminocaproic Acid in Children and Adolescents With Scoliosis Undergoing Posterior Spinal Fusion

Children's Hospital of Philadelphia1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2011年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
1
主要终点
Pharmacokinetic parameters of EACA in participants undergoing Posterior Spinal Fusion

研究概览

简要总结

This study will evaluate the pharmacokinetics of antifibrinolytic drug epsilon-aminocaproic acid (EACA) in children undergoing Posterior spinal fusion surgery (PSF) at The Children's Hospital of Philadelphia (CHOP) who receive EACA at the standard dose reported in the literature for this population and currently in use at CHOP.

详细描述

Posterior spinal fusion surgery (PSF) can be associated with significant blood loss, and perioperative transfusion is common. Various strategies have been employed to decrease intraoperative blood loss and reduce transfusion in children undergoing PSF. The intraoperative administration of the antifibrinolytic drug epsilon-aminocaproic acid (EACA) is one such strategy that has been shown to be effective in this regard. This study will evaluate the pharmacokinetics of EACA in children undergoing PSF at CHOP who receive EACA at the standard dose reported in the literature for this population and currently in use at CHOP.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
8 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Males or females age 8 to 18 years 2)Subjects undergoing posterior spinal fusion surgery 3)Subjects in whom aminocaproic acid administration is planned by the anesthesiology team 4)Parental/guardian permission (written informed consent) and when appropriate, child assent.

排除标准

  • Wards of the State are not eligible
  • Subjects with a history of abnormal renal function -

结局指标

主要结局

Pharmacokinetic parameters of EACA in participants undergoing Posterior Spinal Fusion

时间窗: up to 15 hours

The primary endpoint is the clearance of EACA

次要结局

  • Determine population-specific EACA dosing strategies based on the observed EACA pharmacokinetics(one year)
  • Pharmacokinetic parameters of EACA in participants undergoing Posterior Spinal Fusion(up to 15 hours)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验